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ABSTRACT
The immature phenotype of stem cell derived cardiomyocytes is a significant barrier to their use in translational medicine
and pre-clinical in vitro drug toxicity and pharmacological analysis. Here we have assessed the contribution of non-myocyte
cells on the contractile function of co-cultured human embryonic stem cell derived cardiomyocytes (hESC-CMs) in spheroid
microtissue format. Microtissues were formed using a scaffold free 96-well cell suspension method from hESC-CM cultured
alone (CM microtissues) or in combination with human primary cardiac microvascular endothelial cells and cardiac
fibroblasts (CMEF microtissues). Contractility was characterized with fluorescence and video-based edge detection. CMEF
microtissues displayed greater Ca2þ transient amplitudes, enhanced spontaneous contraction rate and remarkably
enhanced contractile function in response to both positive and negative inotropic drugs, suggesting a more mature
contractile phenotype than CM microtissues. In addition, for several drugs the enhanced contractile response was not
apparent when endothelial cell or fibroblasts from a non-cardiac tissue were used as the ancillary cells. Further evidence of
maturity for CMEF microtissues was shown with increased expression of genes that encode proteins critical in cardiac
Ca2þhandling (S100A1), sarcomere assembly (telethonin/TCAP) and b-adrenergic receptor signalling. Our data shows that
compared with single cell-type cardiomyocyte in vitro models, CMEF microtissues are superior at predicting the inotropic
effects of drugs, demonstrating the critical contribution of cardiac non-myocyte cells in mediating functional cardiotoxicity.
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Drug associated cardiovascular toxicity causes severe morbid-
ity (Schimmel et al., 2004) and is a major reason for attrition
during drug discovery and development (Abassi et al., 2012;
Albini et al., 2010; Laverty et al., 2011). It occurs at all stages
of preclinical and clinical testing and may only be apparent
during post-marketing several years after the cessation of
treatment (Gwathmey et al., 2009; Mellor, 2011). Drug induced
cardiovascular toxicity can result in both functional effects
such as arrhythmia and acute alteration of the contractile
function (inotropy) of the heart, and morphological (struc-
tural) damage to the myocardium (Cross et al., 2015; Laverty
et al., 2011). Evaluation of the potential for both types of
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cardiotoxicity by novel pharmacological compounds is essen-
tial for the discovery of safe drugs. Functional effects such as
arrhythmias are screened for in cell lines over expressing key
cardiac ion channels and cardiomyocyte contractility effects
(positive and negative inotropy) are assessed in freshly iso-
lated adult rat and canine cardiomyocytes (CMs) (Harmer
et al., 2012; Pollard et al., 2010). Although the canine CMs can
be cryopreserved (Abi-Gerges et al., 2013), physiologically rele-
vant human based in vitro models are currently lacking for
risk assessment in man in an integrated system (Cross et al.,
2015). Furthermore, primary CMs from preclinical animal spe-
cies are not amenable to plate-based high throughput screen-
ing (HTS) (Hescheler et al., 1991; White et al., 2004).
Recent advancements in stem cell biology, particularly the
industrial scale production of differentiated stem cell derived
CMs (Abassi et al., 2012), offers an opportunity for developing a
physiologically relevant model system that is amenable to drug
discovery and for regenerative medicine. The utility of human
embryonic stem cell (hESC) and induced pluripotent stem cell
(iPSC) CMs for the prediction of drug-induced functional abnor-
malities is well documented (Abassi et al., 2012; Caspi et al.,
2009; Guo et al., 2011; Laposa, 2011; Rolletschek et al., 2004;
Zeevi-Levin et al., 2012). However, the immature phenotype of
stem cell derived CMs is considered a significant barrier to them
fulfilling this potential in each of these areas (Yang et al., 2014).
When compared with adult CMs, stem cell derived CMs have a
foetal gene expression profile, different myofiber subtypes, and
disorganized sarcomeres (Guo et al., 2011; Yang et al., 2014). This
immature phenotype also lacks T-tubules and is unable to give
an inotropic response to b-adrenergic agonists and other posi-
tive inotropic compounds, which are seen in vivo (Pillekamp
et al., 2012; Pointon et al., 2015).
Approximately 70% of the cells in the human heart are non-
myocytes with cardiac fibroblasts and cardiac endothelial cells
forming the majority of these non-myocyte cells (Brutsaert,
2003; Deb and Ubil, 2014). Cardiac fibroblasts serve a structural
role by providing the extracellular matrix of the heart, mecha-
notransductive cues and paracrine factors that regulate cardio-
myocyte maturation (Bowers et al., 2010; Porter and Turner,
2009; Souders et al., 2009), whilst cardiac endothelial cells form
the myocardial microvasculature, which regulates the supply of
oxygen and free fatty acids to the CMs (Aird, 2007). Cardiac
endothelial cells also release paracrine factors that regulate
cardiomyocyte metabolism, survival, and contractile function
(Brutsaert, 2003; Narmoneva et al., 2004).
Tissue engineering approaches offer great potential for de-
veloping 3D models of heart muscle for use in drug discovery
and development and as cardiac tissue replacement in the
clinic. These approaches include scaffold-free methods such as
microtissues derived from hanging drops or in hydrogels and
monolayer derived cell sheets or patches, and scaffold depen-
dent methods (Hirt et al., 2014). Mixtures of murine lung and
heart derived microvascular endothelial cells were found to en-
hance neonatal cardiomyocyte survival and spatial organ-
ization in peptide hydrogels (Narmoneva et al., 2004). Neonatal
rat fibroblast and CMs co-cultured in agarose hydrogels resulted
in prolonged action potential duration compared to cardiomyo-
cyte cultures alone (Desroches et al., 2012). The maturity of
hESC-CMs was promoted by the presence of non-myocytes pre-
sent in embryoid bodies (Kim et al., 2010). Furthermore, the ma-
turity of hESC-CMs was also enhanced by either human
umbilical vein or hESC-derived endothelial cells, and fibroblast
co-cultures in cell patches (Caspi et al., 2007; Stevens et al., 2009;
Tulloch et al., 2011)
Current in vitro approaches to analyse functional and struc-
tural cardiotoxicity are focussed on utilizing CMs alone (Cross
et al., 2015). Here for the first time, we have assessed the ability
of adult primary cardiac microvascular endothelial cells and
cardiac fibroblasts to induce contractile maturity in hESC-CM in
scaffold-free microtissues. In particular, we have assessed the
contractile phenotype in the context of pharmacological effects
on cardiomyocyte contractility. Spheroid microtissues were
formed from hESC-CM alone or in combination with human pri-
mary endothelial cells and fibroblasts obtained from either car-
diac or noncardiac (dermal) sources. Compared to all other cell
combinations, spheroid microtissues derived from all 3 cardiac
cell types showed remarkably enhanced contractile function in
response to inotropic drugs, which suggested a greater degree
of cardiomyocyte maturity. Evidence of maturity was confirmed
at the molecular and structural level. In addition, we show
that cardiac specific fibroblasts and endothelial cells enhance
and promote maturity through upregulation of the Ca2þ-
binding protein S100A1. We conclude that noncardiomyocyte
cells are critical for promoting an authentic cardiac phenotype
in complex in vitro models and that such models can be
used for more accurate drug safety screening and drug
development.
MATERIALS ANDMETHODS
Preparation of cardiac microtissues
hESC-CMs (Cytiva) were obtained from General Electric
Healthcare (Hertfordshire, UK). Human induced pluripotent
stem cell CMs (hiPS-CMs) were obtained from Cellular
Dynamics International (Madison, Wisconsin). Primary human
cardiac microvascular endothelial cells (hCMECs), primary hu-
man dermal microvascular endothelial cells (hDMECs), primary
human coronary artery endothelial cells), primary human car-
diac fibroblasts (hCFs), and primary normal human dermal fi-
broblasts (NhDFs) were obtained from PromoCell (Heidelberg,
Germany). All primary cells were subcultured prior to microtis-
sue formation according to supplier’s instructions. All primary
cells were detached with pre-warmed Accutase (Sigma, A6964)
for 5 min at 37C, 5% CO2, centrifuged for 3 min at 1200  g be-
fore re-suspension in endothelial basal medium MV2
(PromoCell, C-22221) (supplemented with 5% foetal calf serum
(FCS), epidermal growth factor (EGF; 5 ng ml1), basic fibroblast
growth factor (bFGF; 10 ng ml1), insulin-like growth factor 1
(IGF-1; 20 ng ml1), vascular endothelial growth factor-A (VEGF-
A; 0.5 ng ml1), Ascorbic Acid (1 lg ml1) and Hydrocortisone (0.2
lg ml1). Cell suspensions were counted, diluted and stored at
37C, 5% CO2 for up to one hour while hESC-CM cell suspensions
were prepared. A vial of Cytiva CMs was thawed and suspended
in RPMI 1640 media (Life technologies 61870044) containing b27
supplement (Life technologies 17504) (Pointon et al., 2013).
CMEF/DMEF microtissues: cell suspensions were combined to-
gether to give a concentration of 500 cells per 100 ll comprising
4 parts hESC-CM, 2 parts hCF/NhDF, and 1 part hCMEC/hDMEC
in microtissue media comprising 1 part RPMI (þb27 supplement)
to 1 part Endothelial MV2 (þsupplements). CME/CMF microtis-
sues: cell suspensions were mixed together to give a concentra-
tion of 500 cells per 100 ll comprising 2 parts hESC-CM and one
part hCF/hCMEC in microtissue media. CM microtissues: hESC-
CMs suspension was diluted to 1000 cells per well in RPMI (þb27
supplement) media. In microtissues containing hiPS-CMs,
hESC-CMs were replaced with hiPS-CMs. hiPS-CMs were pre-
pared in iCell thawing media as previously described in Pointon
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et al. (2015). After 48 h culture media was refreshed with iCell
CM maintenance media. Suspensions were subsequently
seeded into round bottom ultra- low adhesion 96-well plates
(Corning Costar, CLS7007).
All microtissue plates were incubated at 37C, 5% CO2 for 14
days with media refreshed every 3–4 days. Experiments were
conducted on microtissues following 14–28 days in culture.
Immunofluorescence
Microtissues were washed in D-phosphate buffered saline (PBS)
until no media remained and subsequently fixed in 4% (w/v)
para-formaldehyde for 1 h at 4C, followed by 6 washes in D-PBS
and stored at 4 C until processing. Microtissues were
permeabilized with 0.5% (v/v) triton X-100/D-PBS overnight at
4C then blocked in 3% (w/v) BSA/TBST block (with 0.1% (v/v)
Triton X-100) for 2 h at room temperature (RT). Primary antibody
was diluted as required in 1% (w/v) BSA/TBST (with 0.1% (v/v)
Triton X-100), block reagent was removed and primary antibody
added overnight at 4 C. Microtissues were washed three times
with TBST (with 0.1% (v/v) Triton X-100) at RT, each time incu-
bated for 1 h. Secondary antibody was diluted 1:1000 in 1% (w/v)
BSA/TBST (with 0.1% (v/v) Triton X-100) and added to the micro-
tissues overnight at 4 C. Microtissues were washed for 1 h with
TBST (with 0.1% (v/v) Triton X-100) at RT and stained with
Hoechst 33342 (2 lg/ml) in TBST (with 0.1% (v/v) Triton X-100)
for 1 h at RT. Microtissues were washed briefly in TBST (with
0.1% (v/v) Triton X-100) before mounting onto microscope slides
with ProLong Gold. Microtissues were imaged using a Zeiss
AxioObserver inverted fluorescence microscope with Apotome
2, using Plan-Apochromat 20/0.8 NA objective. Images were ac-
quired using Zeiss Zen software. In order to allow direct com-
parisons between different microtissues, during image
acquisition each microtissue was processed in a blinded man-
ner and equal exposure was applied for each marker.
Gene expression analysis
Adult left ventricle, foetal heart, and smooth muscle total RNA
were purchased from U.S. Biologic (Memphis, USA). Adult left
ventricle heart total RNA was obtained from one 21-year old
normal male donor with no reported concomitant disease.
hESC-CM total RNA was obtained from hESC-CMs cultured as
described in Pointon et al. (2013). RNA was harvested following
72 h in culture as per the recommended manufacturer instruc-
tions. All primary cells were detached with prewarmed
Accutase (Sigma, A6964) for 5 min at 37C, 5% CO2, centrifuged
for 3 min at 1200 g before lysis in RLT buffer (Qiagen) and
stored at 80 C until processing. Microtissues were pooled and
transferred into a falcon tube, centrifuged at 1200 g for 2 mins
and re-suspended in prewarmed PBS. Microtissues were re-cen-
trifuged at 1200 g for 2 min and lysed in RLT buffer (Qiagen).
Total RNA was extracted using an RNeasy Mini Kit (Qiagen).
A NanoDrop spectrophotometer (NanoDrop Technologies) was
used to quantify RNA samples.
RNA samples were diluted to 20 ng and reverse transcribed
using the SuperScript III first-strand synthesis supermix (Life
technologies). cDNA samples were preamplified using the
TaqMan PreAmp Master mix kit with TaqMan Probes
(Supplementary Table S1), 10 cycles and final stock diluted
1:250. qRT-PCR was performed using 2.5 ll of preamplified
cDNA and TaqMan Gene Expression master mix. qRT-PCR reac-
tions were performed in a 7900 HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, California), 2.5 ll of
preamplified cDNA was used with TaqMan Gene Expression
probes (Supplementary Table S1) and master mix to monitor
amplification under standard cycling conditions. GAPDH was
used as an endogenous control. Relative quantification of gene
expression was performed using the DDCt relative quantitation
method. The mean Ct value was calculated for each gene and
normalized to the endogenous control, fold change relative to
hESC-CM monolayer was determined and data expressed as a
percentage of adult ventricle heart expression levels.
Solutions and compounds
Compounds were obtained from Sigma-Aldrich (Dorset, UK) or
the AstraZeneca compound collection. Compounds were ini-
tially formulated in DMSO as a 1000 stock solution and subse-
quently serially diluted using DMSO. The DMSO stock solutions
were diluted 1000 into the cardiac microtissue media to give
the final test concentrations. The final vehicle concentration
was 0.1% (v/v) DMSO. Where compounds were insoluble in
DMSO, PBS, (Sigma) was used. Caffeine was formulated
in microtissue media at 10 mM.
Video-based edge detection of contractions
Microtissues were transferred onto 0.1% (w/v) gelatin-coated
13 mm plastic coverslips (Thermanox) within a 12-well plate
and incubated at 37C, 5% CO2 for at least 1 h before mounting
onto the IonOptix contractility system. Contractile properties of
microtissues were assessed using a video-based edge detection
method (IonOptix, Dublin, Ireland) (Harmer et al., 2012). A gela-
tin-attached microtissue was placed in a perfusion chamber
(FHC Inc., Bowdoinham, Maine) mounted on the stage of an in-
verted Nikon TE200 microscope (Nikon UK, Surrey, UK). The mi-
croscope stage (Prior Scientific Instruments, Cambridge, UK)
was motorized and controlled remotely. Microtissues were con-
tinuously perfused from a gravity fed system at 2 ml/min with
microtissue media heated to 37 6 1 C using a line heater (Cell
MicroControls, Norfolk, Virginia). The microtissues were field
stimulated with suprathreshold voltage at a pacing frequency
of 1 or 1.5 Hz, with a bipolar pulse of 6 ms duration, using a pair
of platinum wires placed on opposite sides of the chamber con-
nected to a MyoPacer EP stimulator (IonOptix). Microtissues
were imaged at 240 Hz using an IonOptix Myocam-S CCD cam-
era. Digitized images were displayed within the IonWizard ac-
quisition software (IonOptix). The edge of the microtissue of
interest was aligned parallel to the video raster line, by means
of a semi-automated dovecote prism optical system that could
be controlled remotely (Cairn Research, Faversham, UK). Optical
intensity data were collected representing dark and light bands
at the edge of the microtissue of interest. The IonWizard soft-
ware analyzes the periodicity in the optical density by means of
a fast Fourier transform algorithm. The output of this analysis
is a direct real-time measurement of microtissue contraction.
Each compound response was measured from separate ran-
domly selected microtissues on triplicate independent occa-
sions, only one microtissue was assessed at a time. After
microtissues were added to the microscope stage, perfusion
with microtissue media (with 0.1% (v/v) DMSO as the vehicle
control) was immediately started. At this time field stimulation
was also started, and microtissues were left to acclimatize for
approximately 2 min at approximately 37 C, after which at least
30 s of basal contractions were recorded for each microtissue.
Test compounds were applied in a cumulative manner with
each concentration applied for 250 s or until steady-state was
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achieved. Every 3–4 days, 10 lM verapamil was applied as a pos-
itive control, additionally beat rate was assessed at the start
and end of the experimental time frame (14–28 days) to ensure
consistency. Data from any microtissue batches that either did
not elicit a response to 10 lM verapamil and/or varied in beat
rate >10% over the time period were rejected.
Initial analysis was performed using the IonWizard soft-
ware. For each test condition, data for 10–15 contractions were
averaged, using the stimulation time as common reference
point, to give a single representative monotonic contractility
transient. This transient was analysed using the ‘monotonic
transient analysis’ function of the IonWizard software. From
this analysis, peak height, which indicates the percentage of
peak contraction relative to the resting length was used to
quantify microtissue dynamics. Concentration-effect curves
were plotted for each compound and expressed relative to vehi-
cle (0.1% (v/v) DMSO).
Ca21 transient measurements
Microtissues were loaded with 0.2 mmol/l Fura-2-acetoxymethyl
ester (Life technologies, Paisley UK), a calcium-sensitive, ratio-
metric fluorescence dye, for 30 min at RT and kept in the dark.
The same experimental design used for performing contractility
recordings was applied to carry out intracellular Ca2þ measure-
ments (Pointon et al., 2015). The IonOptix system was used to
conduct the experiments, including the Xenon arc lamp, hyper-
switch and myopacer for microtissue stimulation and fluores-
cence excitation, myocam-S for the measurement of edge
contraction, and a fluorescence system interface to integrate
the different components (IonOptix Ltd). The Xenon arc lamp
and fluorescence hyperswitch containing a galvanized mirror
were used to alternate between wavelengths of 340 and 380 nm
at a high frequency. Ca2þ fluorescence was recorded at 510 nm.
Ca2þ traces represent the ratio of Ca2þbound: Ca2þ free Fura-
2-acetoxymethyl ester dye, and hence changes in free intracel-
lular Ca2þ. Simultaneous contraction and Ca2þ recordings for
microtissues were taken while perfusing with their standard
cell culture media containing DMSO 0.1% (v/v) as the vehicle
control when appropriate. A transition period of 250 s was con-
ducted between test concentrations, allowing any compound
induced effects to reach a steady state. Analysis was performed
using the IonWizard software as for contractility
measurements.
S100A1 knockdown
Microtissues were transfected with siRNA using Lipofectamine
RNAiMAX transfection reagent. S100A1 siRNA and negative con-
trol scrambled siRNA was purchased from Life Technologies
(Paisley, UK) Both siRNA probes and Lipofectamine RNAiMAX
transfection reagent were diluted in OptiMEM to give a final
concentration of 0.1% (v/v) for the later. The diluted
Lipofectamine RNAiMAX and siRNA components were com-
bined, mixed well by gentle pipetting and incubated for 5 min at
RT. Cell culture media was removed from the microtissues and
replaced with 100 ll of transfection solution. The plates were
swirled gently to ensure even distribution of the siRNA.
Microtissues were incubated with the transfection solution at
37 C, 5% CO2 for 24 h prior to use.
Data analysis
Concentration-effect curves were plotted for each compound
and expressed relative to vehicle6SD. The molar concentration
of test compound producing 50% inhibition (IC50) or 50% re-
sponse (EC50), was calculated using GraphPad Prism (La Jolla,
California) to fit data to a 4-parameter nonlinear regression
curve. Each IC50/EC50 was generated in triplicate for each com-
pound and geometric means were subsequently calculated. F-
tests to compare the concentration response curves respectively
were performed using GraphPad Prism (La Jolla, Califorrnia). T-
tests and ANOVA to compare the conditions were performed
using GraphPad Prism (La Jolla, Califorrnia).
RESULTS
Development of Cardiac Microtissues
hESC-CMs were cultured either alone (CM microtissues) or with
hCMECs and hCFs (CMEF microtissues) in 96-well round-bot-
tomed ultra-low adhesion plates. Following two weeks in cul-
ture, microtissues with uniform size and shape, measuring
200 lm in diameter, with equal light exposure were formed
(Figs. 1A and 2A). Immunofluorescence imaging of specific car-
diac cell types: cardiomyocyte (alpha actinin, ACTN2), endothe-
lial (CD31), and fibroblast markers (collagen I, COL1A1) was
utilized to determine the morphology and cellular architecture
of the microtissues. The presence of hCMECs (CD31) (Figure 1B)
and hCFs (collagen 1) (Figure 1C) were confirmed in the CMEF
microtissue and located in close proximity to the hESC-CMs,
displaying even cell type distribution throughout. Staining of a-
actinin highlights hESC-CMs within the CMEF and CM microtis-
sues. Differences in cardiac striations between the CM and
CMEF microtissues were revealed following imaging of a-actinin
with the latter displaying striations with enhanced organization
and elongation (Figs. 1D and 2D).
CMEF Microtissues Display Improved Contractile
Properties
To determine the contraction and relaxation kinetics of the
microtissues, we used the IonOptix cell geometry measurement
system and IonWizard software. This allowed measurement of
movement of microtissues in real time at 37 6 1C, with a con-
tinuous flow of cell culture media, while spontaneously beating
and following field stimulation at 0.5, 1, 2, and 3 Hz (i.e. equiva-
lent to 30, 60, 120, and 180 beats/min). Under these conditions
both microtissues displayed typical spontaneous synchronized
contractility transients, with a spontaneous beat rate of 54 6 5
and 24 6 6 beats/min in CMEF and CM microtissues, respec-
tively (mean6SD, n¼ 3) (Figs. 3C and D); P value < .01. This
spontaneous beat rate for each tissue remained constant over
the period of study (14–28 days) confirming the viability of tis-
sues (Figs. 3A and B). Furthermore, both microtissues were able
to maintain synchronized, typical contraction transients follow-
ing field stimulation (7 V for 6 ms) at 0.5, 1, 2, and 3 Hz (Figs. 3E
and F), resulting in a mean beat rate of 296 1.1, 5961.5, 9061.5,
and 1236 8.5 beats/min, respectively in CMEF microtissues and
2163, 5864.1, 9163.2, and 1196 5.5 beats/min, respectively in
CM microtissues (n¼ 36SD). As changes in [Ca2þ]i are intrinsi-
cally linked to changes in cardiomyocyte contraction, we inves-
tigated the relationship between these parameters in both
microtissues. In field-stimulated (0.5, 1, 2, and 3 Hz) CM and
CMEF microtissues, the rise in [Ca2þ]i occurred before the initia-
tion of contraction (Figs. 3G and H). Both microtissues showed a
frequency–response relationship: as the frequency increased,
the amplitude of the [Ca2þ]i and contraction transients de-
creased (n¼ 3) (Figs. 3I and J). However, the CMEF microtissue
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produced Ca2þ transients of that were of higher amplitude at 1,
2, and 3 Hz. In order to assess the functionality of Ca2þhandling,
microtissues were acutely exposed to caffeine (10 mM) through
a short timescale exposure in the perfused media and contrac-
tion transients monitored during spontaneously beating condi-
tions. CMEF microtissues produced an immediate transient
increase in contraction number and amplitude, followed by ces-
sation of contraction (Figure 3K). Whereas in CM microtissues;
contractions gradually decreased in both number and ampli-
tude prior to cessation of contraction (Figure 3L).
Due to these observed differences in Ca2þhandling, the
pharmacological response following 1.5 Hz field stimulation to
FIG. 1. Structural characterization of CMEF microtissues. A, DIC image of a representative CMEF microtissue. Immunofluorescent staining of CMEF microtissues for (B)
endothelial marker, CD31 (green); (C) fibroblast marker, collagen I (COL1A1) (red); (D) cardiac striation marker, ACTN2 (white); (E) nuclei stain, hoechst (blue) and (F)
Merge of CD31 (green), COL1A1 (red), ACTN2 (white) and hoechst (blue). Scale bar represents 50lm.
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a known in vivo negative (verapamil) and positive (dobutamine)
inotrope was assessed to determine the suitability of these
microtissues for the identification and investigation of changes
in cardiac contractility. Contractility transients were recorded
following vehicle control (0.1% (v/v) DMSO) and each compound
on three independent occasions (n¼ 3). To take into account dif-
ferences in basal contraction kinetics between microtissues, all
data was normalized to the vehicle response (0.1% DMSO (v/v))
in each microtissue. Consequently any differences observed are
a direct result of compound exposure. In both CMEF and
FIG. 2. Structural characterization of CM microtissues. A, DIC image of a representative CM microtissue. Immunofluorescent staining of CM microtissues for (B) endo-
thelial marker, CD31 (green); (C) fibroblast marker, collagen I (COL1A1) (red); (D) cardiac striation marker, ACTN2 (white); (E) nuclei stain, hoechst (blue) and (F) Merge of
CD31 (green), COL1A1 (red), ACTN2 (white) and hoechst (blue). Scale bar represents 50lm.
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FIG. 3. Functional characterization of CMEF and CM microtissues. Contractile properties (edge) and Ca2þkinetics were assessed using a video-based edge detection
method (IonOptix, Dublin, Ireland). Microtissues were formed and incubated for 14 days prior to measurment of the spontaneous beat rate in both CMEF (A) and CM
microtissues (B) at the start (day 14) and end (day 28) of the experimental period. Plates were incubated at 37 C, 5% CO2 for 14 days with media refreshed every 3–4
days. Experiments were conducted on microtissues following 14–28 days in culture. Representative trace showing contraction (edge) kinetics in spontaneous
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CM microtissues, 10 lM verapamil reduced the contractility
transients (Figs. 3M and N), whereas following 10 lM
dobutamine the CMEF microtissue produced a positive
inotropic response with an increase in contractile amplitude,
but no effect was observed in the CM microtissue (Figs. 3O
and P). This data demonstrates the potential utility of microtis-
sues for the detection and investigation of cardiac contractility
in vitro.
The potential of cardiac microtissues to detect a pharmaco-
logically diverse panel of 12 inotropic compounds with in vivo
changes in cardiac contractility (5 negative and 7 positive ino-
tropes) and 5 noninotropic compounds without in vivo changes
in cardiac contractility were assessed following field stimula-
tion at 1.5 Hz. Cumulative concentration response curves and
corresponding IC50/EC50 values were obtained for each com-
pound in both CMEF and CM microtissues. Overall, all positive
inotropes tested were detected with an increase in amplitude of
contraction in CMEF microtissues. In comparison, in CM micro-
tissues 4 out of 7 positive inotropes were detected; however, the
direction of response was the reverse to that observed in vivo for
all except epinephrine (Table 1). For example, the Naþ/Kþ
ATPase membrane pump inhibitor, digoxin, increased the am-
plitude of contractility transients in CMEF microtissues, produc-
ing an EC50 value of 3.54 lM. In contrast, in CM microtissues a
decrease in the amplitude of contractility transients was ob-
served, resulting in an IC50 value of 0.4 lM. Additionally,
following exposure to 5 negative inotropes, all were correctly
detected in CMEF, but only 3 (diltiazem, doxorubicin, verapamil)
were detected in the CM microtissue (Table 1). For example, the
b1-adrenergic receptor antagonist, atenolol, resulted in IC50
values of 0.94 lM and above 100 lM in CMEF and CM
microtissues respectively. This data indicates the superior util-
ity of CMEF microtissues compared to CM microtissues with re-
spect to in vitro to in vivo pharmacological correlation and
relevance.
Contractile Pharmacology Is Dependent upon a Cardiac
tri-Culture System
In order to further explore these differences in responses be-
tween CMEF and CM microtissues, three additional microtissues
were evaluated. The first additional microtissue contained
hESC-CMs and hCMECs (CME microtissue), the second con-
tained hESC-CMs and hCF (CMF microtissue) and the third
microtissue contained both endothelial and fibroblasts from a
dermal vascular bed with hESC-CMs (DMEF microtissue;
Supplementary Figure S1). Two negative (atenolol, lapatinib)
and two positive (digoxin, dobutamine) inotropic pharmacologi-
cally diverse compounds were assessed to identify if one partic-
ular cell type within the CMEF microtissue was responsible for
the differences observed. Following exposure to the b1-adrener-
gic receptor antagonist, atenolol, a negative inotropic response
was observed in both the CMEF and CMF microtissues, resulting
in IC50 values of 0.94 lM; no effect was observed in CM, CME, or
DMEF microtissues (Figure 4A). However the EGFR-1/EGFR-2
(Her2) inhibitor, lapatinib (Albanell and Gascon, 2005), produced
contracting CMEF and CM microtissues (C), the number of contractions over a period of time were quantified (D) (n>3, mean6SD). Representative recordings of CMEF
(E) and CM microtissue (F) contractions following field stimulation at 0.5, 1, 2, and 3 Hz. Representative traces following measurement of Ca2þ (red trace) and contraction
transients (edge) (blue trace) in (G) CMEF and (H) CM microtissues following field stimulation at 0.5, 1, 2, 3 Hz with 7V for 6 ms. Summary of the frequency-response rela-
tionship for contraction (edge) (I) and [Ca2þ]i (J) at 0.5, 1, 2, and 3 Hz, n¼3, (6) SD in both CMEF (open bars) and CM microtissues (solid bars) .A representative experiment
showing the effect of 10 mM caffeine on contraction transients elicited at 1.5 Hz stimulation in CMEF (K) and CM (L) microtissues.20 s of vehicle control (0.1% DMSO)
contraction transients (left side) and >10 s of 10mM caffeine contraction transients (right side) are shown. Representative contractility transients elicited at 1.5 Hz stim-
ulation in CMEF (M) and CM (N) microtissues following 10 lM verapamil. 20 s of basal contraction transients (left side) and 20 s of 10 lM verapamil contraction transients
(right side) are shown. . Representative contractility transients elicited at 1.5 Hz stimulation in CMEF (O) and CM (P) microtissues following 10lM dobutamine. 20 s of
basal contraction transients (left side) and 20s of 10 lM dobutamine contraction transients (right side) are shown. *P-value < .01. (Full color version available online.)
TABLE 1. Contractile Responses of CMEF and CM Microtissues to Known Pharmacological Agents
Compound Drug Target CMEF Microtissue
IC50/EC50 (lM)
CM Microtissue
IC50/EC50 (lM)
In Vivo Effect
Amoxicillin b-lactam antibiotic NE — NE
Paracetamol Cyclooxygenase inhibitor NE — NE
Sildenafil PDE-5 inhibitor NE — NE
Enalapril Angiotensin-converting enzyme inhibitor NE — NE
Tolbutamide ATP-sensitive potassium channel inhibitor NE — NE
Atenolol b1-adrenergic receptor antagonist 0.94 # NE ve inotrope
Verapamil L-type Ca2þ channel blocker 0.11# 1# ve inotrope
Diltiazem L-type Ca2þ channel blocker 0.38# 2.47# ve inotrope
Doxorubicin Intercalates DNA 1.16# 1.16# ve inotrope
Lapatinib EGFR-1/EGFR-2 (Her2) inhibitor 0.86# NE ve inotrope
Epinephrine Nonselective adrenergic receptor agonist 0.07" 0.0012" þve inotrope
Glibenclamide ATP-sensitive potassium channel inhibitor 0.8" NE þve inotrope
Levosimenden Calcium sensitizer (binds cardiac troponin C) 0.13" NE þve inotrope
Digoxin Inhibits Naþ/Kþ ATPase membrane pump 3.54" 0.4# þve inotrope
Dobutamine b1-adrenergic receptor agonist 0.29" 0.03# þve inotrope
Isoproterenol b1-adrenergic receptor agonist 0.0004" 0.00009# þve inotrope
Milrinone PDE-3 inhibitor 83.68" NE þve inotrope
Contractile response of CMEF and CM microtissues to a panel of 12 pharmacologically diverse inotropic compounds. Drug targets and known in vivo effects are shown.
IC50/EC50 shown (n¼3). Direction of inotropic response highlighted with arrows (" increase in inotropy, #decrease in inotropy). Correct prediction compared to in vivo
effect highlighted in green, incorrect prediction compared with in vivo effect highlighted in red.
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a negative inotropic response in both CMEF and CME
microtissues resulting in IC50 values of 0.86 and 1 lM respec-
tively; no effect was observed in CM, CMF, and DMEF microtis-
sues (Figure 4B).
Following exposure to the known in vivo positive inotropes,
dobutamine, and digoxin, a positive inotropic response was
only observed in the CMEF microtissue resulting in EC50 values
of 0.3 and 3.54 lM, respectively, the converse response was
observed in CM, CME, and CMF microtissues, resulting in IC50
values of 0.02, 0.01, and 0.001 lM respectively following dobut-
amine and 0.7, 0.9, and 0.3 lM, respectively following digoxin
(Figs. 4C and D). DMEF microtissues displayed no response to ei-
ther positive inotrope. These results highlight the requirement
of both endothelial and fibroblast cells of cardiac origin to be
present for the enhanced pharmacological response to be
observed. To confirm that the enhanced pharmacological re-
sponse of the multicellular microtissue was not restricted to
microtissues composed of hESc-derived CMs we also utilized
iPSc-derived CMs. Two microtissues containing hiPS-CMs were
prepared; hiPS-CMs in combination with hCMECs and hCF (hiPS
CMEF) and hiPS-CMs alone (hiPS CM). Following exposure to the
known in vivo positive inotrope, dobutamine, a positive inotro-
pic response was again only observed in the hiPS CMEF micro-
tissue, resulting in an EC50 value of 0.39 lM in hiPS CMEF; the
converse response was observed in the hiPS CM microtissue, re-
sulting in an IC50 value of 0.1 lM (Figure 4E). These results indi-
cate the suitability of both hESC-CM and hIPC-CM microtissues
to detect changes in cardiac contractility.
FIG. 4. The contractile response of cardiac microtissue models to known inotropic compounds. Concentration-effect curves of CMEF, CM, DMEF, CME, and CMF micro-
tissues to (A) atenolol, (B) lapatinib, (C) dobutamine, and (D) digoxin. E, concentration-effect curves of microtissues containing hiPS-CMs alone or in combination with
hCMECs and hCF response to dobutamine. Data expressed relative to vehicle (0.1% (v/v) DMSO) (n¼36SD). *P-value < .05.
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In order to provide further mechanistic insight into possible
explanations for these enhanced physiologically relevant re-
sponses in CMEF microtissues, gene expression analysis of a
panel of genes involved in microtubule and sarcomere assembly
(S100A1; S100 calcium-binding protein A1, TCAP; titin-cap), car-
diovascular function (ADRB1; b1-adrenergic receptor, PDE3A;
phosphodiesterase 3, KCND3; potassium voltage-gated channel
Kv4.3), nitric oxide production (NOS3; nitric oxide synthase 3)
and cardiomyocyte maturity (MYH6; myosin heavy chain 6,
MYH7; myosin heavy chain 7) were evaluated. When compared
with the expression of these genes in monolayer hESC-CMs and
CM microtissues, CMEF microtissues showed increased expres-
sion of S100A1, TCAP, PDE3A, NOS3 and KCND3 (P value < .01)
with fold changes of 0.007, 0.12, 0.07, 0.23, and 0.1 in CMEF
microtissues and 0.0007, 0.03, 0.03, 0.08, and 0.05 in CM micro-
tissues compared to adult ventricular tissue, respectively (Figs.
5A–D and F). These expression levels are comparable to those
observed in foetal cardiac tissue. Whereas, ADRB1 expression
was similar to adult ventricle tissue in both CMEF and CM
microtissues with fold changes of 1.9 and 1.3 (P value < .05), re-
spectively, this is compared with a fold change of 0.02 in mono-
layer hESC-CMs (Figure 5E). MYH7, a predominantly adult
myosin chain, was expressed at equal levels in CMEF and CM
microtissues with a fold change of 0.15 relative to adult ventri-
cle tissue, an expression level comparable to foetal heart and
hESC-CM monolayer. MYH6, predominantly a foetal myosin
chain, was highly expressed in CMEF and CM microtissues, 13-
and 5–fold, respectively (P value < .01), compared with adult
ventricle (Figs. 5G and H).
S100A1 Regulates Contractile Maturity
S100A1, a cardiac Ca2þ regulator (Maco et al., 2001), showed en-
hanced upregulation specifically within CMEF microtissues
(Figure 5A). Considering the different caffeine-ICR responses of
the CMEF microtissues we hypothesized that S100A1 may have
a role in the contractile maturity of the CMEF microtissues. To
confirm this, short interfering RNA (siRNA)-mediated knock-
down of S100A1 was performed in CMEF microtissues and its ef-
fect on caffeine response studied. Partial knockdown of S100A1
mRNA expression by 42%6 2.58 (mean6SD) (Figure 6A), re-
sulted in a complete loss of the transient increase in CMEF con-
traction amplitude following caffeine exposure (Figs. 6B and C).
DISCUSSION
The human heart is composed of CMs, fibroblasts and endothe-
lial cells, which facilitate normal cardiac development and
physiological cardiac function (Brutsaert, 2003). Here we have
shown that adult cardiac nonmyocyte cells can promote
FIG. 5. Gene expression upregulation in cardiac microtissues. Fold change of (A) S100A1, (B) TCAP, (C) PDE3A, (D) NOS3, (E) ADRB1, (F) KCND3, (G) MYH6, and (H) MYH7
mRNA expression in foetal heart tissue, cardiac microtissues, and individual cardiac cells relative to adult heart tissue (n¼3,6SD) was determined by qRT-PCR.
*P-value < .01, **P-value < .05.
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contractile maturity of embryonic stem cell derived CMs in vitro
by co-culturing as a 3D microtissue to better recapitulate the
in vivo cellular physiology and pharmacological response.
The advent of stem-cell derived human CMs offers the po-
tential for more physiologically relevant preclinical safety test-
ing for drug-induced cardiotoxicity and disease understanding.
However, it has been widely reported that hESC-CMs structur-
ally resemble embryonic CMs and lack the complex communi-
cations required for efficient excitation-contraction coupling
(Kehat et al., 2003). In the adult CM, isoproterenol, a b1-adrener-
gic receptor agonist, displays positive inotropy (increase in con-
traction amplitude), and positive chronotropy (increase in
contraction rate). hESC-CMs elicit positive chronotropy but no
positive inotropy suggesting hESC-CMs have some degree of b1-
adrenergic receptor expression, but again highlighting the im-
maturity of this cell model (Robertson et al., 2013). Here we have
demonstrated the relatively low level b1-adrenergic receptor ex-
pression found in hESC-CMs can be increased using three di-
mensional cell culturing (Figure 5E).
The enhanced in vitro to in vivo pharmacological correlation
observed in the CMEF microtissues compared with the CM
microtissues was evident across a range of different negative
inotropic drugs targeting a diverse set of targets (Table 1), eg,
the b1-adrenergic receptor (atenolol) and EGFR-1/EGFR-2 re-
ceptor (lapatinib) and positive inotropic drugs targeting the b1-
adrenergic receptor and Na/KþATPase (digoxin). The ability of
atenolol to inhibit contraction in the absence of exogenous
catecholamines can be potentially explained by either the in-
verse agonist properties of b-adrenoceptor antagonists (Varma
et al., 1999) or endogenous secretion of catecholamines by the
microtissue (Sorriento et al., 2012). The positive pharmacological
correlation evident in the CMEF was restricted to cardiac endo-
thelial cells and fibroblasts, as substitution with dermal equiva-
lents of microvascular endothelial cells and fibroblasts in the
microtissue did not reconstitute the positive correlation. This
difference between the effect of CMEF microtissues compared
with CM microtissues was not restricted to the use of hESc-de-
rived CMs as a similar effect on contractility with dobutamine
was observed using iPSc-derived CMs (Figure 4E).
This positive pharmacological effect was not due to differ-
ences in cellular architecture within the microtissues as the
dermal nonmyocyte cells and cardiac nonmyocyte cells formed
multicellular microtissues with a similar structure. However,
differences in gene expression between the different multicellu-
lar microtissues suggest that the cardiac derived nonmyocytes
are capable of inducing a transcriptional program within the
CMs that results in pharmacological maturity. Analysis of gene
expression in the different cardiac microtissues revealed that
the Ca2þbinding protein S100A1 was upregulated in the CMEF
microtissue relative to the CM microtissue (Figure 5A). The im-
portance of this gene upregulation was confirmed using a par-
tial siRNA-mediated knockdown CMEF model which
highlighted a loss of inotropic response to a short timescale ex-
posure of the Ca2þmobilizing agent caffeine. Studies have
FIG. 6. S100A1 regulates contraction in response to caffeine. CMEF microtissues were formed and incubated for 14 days prior to transfection with 10 nM nonsilencing
siRNA (ve control) and 10 nM S100A1 siRNA. A, RNA was extracted from microtissues and expression of GAPDH and S100A1 mRNA analysed by qRT-PCR (n¼ 3,6SD).
Contractile response recorded using the IonOptix cell geometry system under vehicle control (0.1% v/v DMSO) and 10 mM caffeine in (B) nonsilencing siRNA control
CMEF microtissue and (C) S100A1 siRNA transfected CMEF microtissue (results from 1 experiment representative of 3 separate experiments).
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previously highlighted a correlation between S100A1 protein ex-
pression and inotropy response (Bennett et al., 2014).
Furthermore, adenoviral mediated over-expression of S100A1
improved b1 adrenergic mediated contractile reserve in CMs
from failing human hearts, suggesting that this protein may
play multiple roles in regulating cardiomyocyte physiology
(Brinks et al., 2011).
In adult CM, Ca2þ induced Ca2þ release (CICR) from the sar-
coplasmic reticulum contributes almost 70% of the total
Ca2þ release. In contrast, immature CMs demonstrate
Ca2þ transients that are smaller and slower (Robertson et al.,
2013), with most cation influx of Ca2þ through the cell mem-
brane (Liu et al., 2007). This results in abnormal diffusion of
Ca2þ into the cell and reduces the synchrony in contraction nec-
essary for large force generation. There is also consensus that
intracellular Ca2þstores are smaller than in adult CM and less
reliant upon ryanodine receptors for Ca2þ release. Ca2þhandling
and response to compounds that modify Ca2þhandling varies
greatly between immature and mature CMs. The differences in
the amplitude of the Ca2þ transient between CMEF and CM
microtissues, that were not evident for the edge transient (Figs.
3G and H), could represent a difference in the excitation–
contraction coupling process between the two microtissues,
potentially due to differences in Ca2þhandling and storage.
Indeed, Ca2þcurrents have been recorded in both endothelial
cells (Tran et al., 2000) and cardiac fibroblasts (Li et al., 2009),
therefore Ca2þ transients in these cell types could contribute to
the increase in Ca2þ transient amplitude in the CMEF microtis-
sue. The increased Ca2þ transient amplitude, response to
Ca2þdyshomeostatic compounds (for example levosimenden
and caffeine) and increased expression of the Ca2þhandling
protein S100A1 suggests a three dimensional co-culture with
adult cardiac nonmyocytes can improve the immature
Ca2þhandling state of hESC-CM’s.
Together these findings show the promotion of maturity is
very much multi-parameter dependent. However, it should be
noted that despite achieving a functionally relevant degree of
maturity, this in vitro myocardial model still lacks some of the
characteristics of fully matured myocardial tissue. Additional
studies to assess structural maturity such as T-tubule formation
would provide further insight. Major morphological changes oc-
cur during prenatal to postnatal cardiac development as CMs
adapt to changes in hemodynamic forces (Zimmermann, 2013).
Adult CMs are large and cylindrical, approximately 150 lm in
length. Despite the CMEF microtissue displaying improved ma-
turity with regard to contractile function, the multicellular
microtissues have a diameter of 200 lm, this probably re-
flects the lack of hemodynamic load during microtissue
formation and maturation. Recent approaches to model tensile
forces during microtissue development have utilized a micro-
fabricated platform (Thavandiran et al., 2013) and fibrin-based
engineered heart tissue between 2 hollow elastic silicone
posts (Hirt et al., 2012). These engineered platforms promote
cardiac maturation-associated gene expression similar to our
study. However, we have provided a pharmacological interroga-
tion of functional maturity in a scaffold-free multicellular
microtissue.
The lack of a readily available source of human adult CMs for
translation medicine means these stem cell-derived CMs have
become fundamental to in vitro cardiac research. Our previous
data, and that of others, has shown that stem-cell derived CMs
are able to analyse both functional (Pointon et al., 2015) and
structural cardiotoxicity (Clements et al., 2015; Pointon et al.,
2013). By improving the in vitro culture of these CMs to better
recapitulate the in vivo cellular microenvironment within the
myocardium, we have developed a novel model with enhanced
pharmacological relevance. Importantly, this microtissue model
can be utilized for analysis of functional and potentially struc-
tural cardiotoxicity, is amenable to high-throughput production
and has the potential to highly impact cardiac research and anal-
ysis of drug-induced cardiovascular toxicity.
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Supplementary data are available online at http://toxsci.
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